Epirium Bio to Present New MF-300 Clinical and Translational Data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, announced today that new clinical and translational data for MF-300 will be presented in two oral sessions at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference (ICFSR) 2026, taking place March 10-12 in Washington, DC.
Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, immunological and fibrotic diseases, today announced outcomes from its Type C meeting with the Food and Drug Administration (FDA). Epirium has received written feedback from the FDA on its Phase 2b trial plan to evaluate MF-300, an oral 15-PGDH enzyme inhibitor for the treatment of age-related sarcopenia. Epirium has previously completed a positive Phase 1 clinical trial of MF-300, including older adult cohorts.
Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced additional results from the older adult follow-on cohorts from its completed Phase 1 trial evaluating MF-300, a novel therapy in development for primary or age-related sarcopenia. In the older cohorts, the study met its primary safety endpoint, and the evaluated dose of MF-300 - corresponding to the maximum estimated pharmacologic effect - was generally well tolerated, with no early discontinuations. In older adults, MF-300 continued to demonstrate the desired pharmacodynamic (PD) responses with a profile consistent with the younger study participants. PD responses were observed early and sustained over time, with effects that differentiated from placebo, supporting target engagement and biologic activity. Pharmacokinetic (PK) analyses demonstrated exposures consistent with younger adults, the observed half-life supporting convenient once-daily oral dosing.
Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America Annual Scientific Meeting 2025
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, presented Phase 1 data for its lead candidate, MF-300, at the Gerontological Society of America’s (GSA) annual meeting held November 12-15, 2025, in Boston, MA.
Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia
Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced positive results from its Phase 1 trial evaluating MF-300, a novel therapy in development for sarcopenia. The primary endpoint of safety was achieved, and all doses of MF-300 studied were generally well tolerated with no subject discontinuations. MF-300 produced dose-related pharmacodynamic (PD) responses which were observed early and sustained over time, whereas placebo showed no meaningful changes, supporting target engagement and biologic activity. Pharmacokinetic (PK) analyses demonstrated dose-related increases in exposure, and the observed half-life supports convenient once-daily oral dosing.
Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters featuring preclinical data on MF-300 at the International Conference on Frailty and Sarcopenia Research (ICFSR), taking place March 12-14, 2025, in Toulouse, France. These presentations highlight the beneficial effects of MF-300 on muscle function in mouse models of aging.
